Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07132177 · ClinicalTrials.gov registry record · Phase 2

Targeted Naltrexone to Support Individuals Participating in Dry January

A Phase 2 study of Alcohol Misuse, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT07132177: Recruiting Phase 2 study of Alcohol Misuse, sponsored by Brigham and Women's Hospital.

NCT07132177 is a Phase 2 study of Alcohol Misuse that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 1,622-participant average among 8 other Alcohol Misuse trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07132177, a Phase 2 study of Alcohol Misuse, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This pilot open-label study will assess the feasibility, acceptability, and preliminary efficacy of targeted (as-needed) oral naltrexone in individuals participating in "Dry January," a month-long voluntary abstinence or reduction in alcohol use. Participants who do not meet criteria for alcohol use disorder (AUD) but are interested in reducing or abstaining from alcohol will receive a 31-day supply of 50mg oral naltrexone to take either prior to anticipated drinking or daily as a precaution. The study will evaluate recruitment, retention, adherence, and safety, as well as changes in alcohol use patterns, craving, mood, liver function, and quality of life. A qualitative interview at follow-up will explore participants' experiences using naltrexone during Dry January. Results will inform future randomized trials testing low-intensity, scalable interventions for non-treatment-seeking individuals seeking to reduce alcohol consumption.

Primary Outcome

Recruitment: Proportion of those screened who successfully enroll in the trial. Greater than 75% enrollment will be considered excellent, and greater than 50% enrollment will be considered good.

Conditions Studied

Interventions

  • DRUG Naltrexone (oral tablets)

Study Locations (1)

Massachusetts

  • Brigham and Women's hospital - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-11-03
Est. Completion 2026-05-01
Phase Phase 2
Brigham and Women's Hospital

937 total trials

What NCT07132177 shows while recruiting

NCT07132177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,622-participant average among 8 other Alcohol Misuse trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Alcohol Misuse appearing as the primary indexed condition, and to 1 intervention - of which Naltrexone (oral tablets) is the first listed.

NCT07132177 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07132177 about?

NCT07132177 is a clinical study titled "Targeted Naltrexone to Support Individuals Participating in Dry January". This pilot open-label study will assess the feasibility, acceptability, and preliminary efficacy of targeted (as-needed) oral naltrexone in individuals participating in "Dry January," a month-long voluntary abstinence or reduction in alcohol use. Participants who do not meet criteria for alcohol use...

What is the current status of trial NCT07132177?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-11-03. Estimated completion is 2026-05-01.

What conditions does trial NCT07132177 study?

This clinical trial studies the following conditions: Alcohol Misuse.

What interventions are being tested in trial NCT07132177?

The interventions under investigation include: Naltrexone (oral tablets) (DRUG).

Who is sponsoring clinical trial NCT07132177?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07132177 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Misuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07132177's enrollment target sits among peer trials

20 9th of 8 the lowest of 8 other Alcohol Misuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Misuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07132177, the US trial registry maintained by the National Library of Medicine. NCT07132177 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.